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BACKGROUND Warfarin is commonly used for stroke risk reduction
in atrial ﬁbrillation (AF). While effective at reducing the risk of
ischemic stroke, it increases the risk of bleeding. Left atrial appendage
closure (LAAC) provides embolic protection and enables most patients
to discontinue lifelong oral anticoagulation (OAC). This analysis
sought to quantify the cost to the US Centers for Medicare & Medicaid
Services (CMS) of bleed-related complications with warfarin compared
to LAAC with the WATCHMAN.
METHODS A Markov model was developed to assess cost of bleeding
complications with LAAC versus warfarin from a CMS perspective over
a 20-year time horizon. Probabilities for major bleeding events were
determined from a pooled analysis of the PROTECT AF and PREVAIL
trials. For costing purposes, LAAC patients were assumed to adhere to
the OAC regimen in these study protocols. According to published
data, bleeding history and age were modeled to increase bleeding risk.
Bleed-related mortality risk was obtained from 2012 US HCUP data.
Costs of bleeds included direct costs due to in-patient care as well as
long-term disability costs. Cost data were taken from the literature
and 2015 US DRGs/CPTs.
RESULTS The procedural-related bleeding event rate with LAAC was
4.9%, with an average cost to CMS of $176 per patient. Modeled post-
procedural bleed event rates were 5.1% for LAAC compared to 11.5%
for warfarin. Hemorrhagic stroke accounted for 18% and 24% of these
bleed events for LAAC and warfarin, respectively. At 20 years, direct
costs for non-procedural bleeds were $3,111 per LAAC patient and
$9,244 per warfarin patient. On average, long-term disability costs
accounted for an additional $3,440 per LAAC patient and $10,502 per
warfarin patient. Total bleeding costs were $13,195 greater with
warfarin than LAAC.
CONCLUSIONS This analysis suggests that among AF patients at risk
for stroke, bleeding-related costs to CMS are nearly 3 times greater
with chronic warfarin compared to LAAC with WATCHMAN. This
should be considered when assessing the overall cost beneﬁt for non-
pharmacological, stroke risk reduction therapies in AF.
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BACKGROUND Outcome data comparing ischemic functional mitral
regurgitation (I-FMR) versus non-ischemic FMR (NI-FMR) following
percutaneous repair are not currently available in the literature. We
aimed to describe the early and 12-month results following MitraClip
device implantation regarding the two etiologies.
METHODS Between January 2011 December 2012 the Transcatheter Valve
Treatment Sentinel Pilot Registry included 452 patients with FMR who
underwent MitraClip procedure in 25 centers of 8 European countries.
RESULTS The prevalent etiology was I-FMR (235 patients, 52.0%). I-FMR
group had a signiﬁcant higher proportion of men (74.9 vs 59.9%, p<0.001)
and surgical risk (logistic EuroScore 24.818.2 vs 18.816.3, p<0.001).
Acute procedural success was high (95.8%) and similar between groups
(p¼0.48). Patients with I-FMR required a higher, albeit not signiﬁcant,
number of clips to reduce MR (p¼0.08). In-hospital mortality was low
(2.0%) without signiﬁcant differences between etiologies. Both I-FMR and
NI-FMR showed a signiﬁcant post-clip improvement in NYHA functional
class with the majority of patients exhibiting a NYHA class<II (82.6 and
74.2%, respectively). EuroSCORE,an impairedejection fraction (i.e.<30%),
pre-procedural chronic kidneydiseaseand the inability to reduce themitral
regurgitation represented the most important factors affecting both sur-
vival and re-hospitalization in FMR patients. Estimated overall 1-year
mortality and re-hospitalization rates were 15.0 and 25.8% respectively,
However, even though no signiﬁcant differences in terms of long-term
outcomeswere demonstrated, the survival curve showed a trend toward a
gradual decline in the I-FMR group versus a stabilization in the NI-FMR
group after 6 months. Paired echocardiographic data, available for 264
consecutive patients, showed a persistent improvement of MR at 1 year in
bothI-FMR and NI-FMR (6.6 and 5.4% of the patients with severe MR,
respectively). Despite a signiﬁcant overall reverse atrial remodeling after
clip, suggestive for an effective correction of the volume overload, no sig-
niﬁcate changes in left ventricular volumes have been demonstrated.
However, although both etiologies, showed a signiﬁcant acute decrease in
pulmonary pressure, only the I-FMR group demonstrated a concomitant
signiﬁcant acutedecrement inatrial volume (DLAV13.6ml,p¼0.016),while
at the 1-year follow-up a signiﬁcate reductionwas detected in both groups.
CONCLUSIONS This independent large cohort showed that percuta-
neous “edge-to-edge” therapy is associated with early and long-term
improvement of MR severity and functional status both in I-FMR and
NI-FMR groups. However some, albeit not signiﬁcant, differences
detectable both in the echocardiographic patterns and long-term
outcomes, suggest the possibility that the beneﬁt of Mitraclip differ
depending on the etiologies of mitral regurgitation prompting the
need for further large controlled studies investigating the underlying
pathogenetic mechanisms of FMR.
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> 60 mm P-value
Nr of patients 5252 4558 1565 544
Basic characteristics
Age, years 63.612.1 63.111.9 63.011.9 64.011.5 0.07
Male gender, % 74.4 77.6 78.9 82.0 <0.001
Total stent lengths, mm 15.42.9 27.64.3 48.45.7 82.018.7 <0.001
DAPT at baseline, % 72.3 73.5 74.6 73.4 0.26
1-year outcome
All death, % 1.56% 1.65% 1.98% 2.02% 0.63
Cardiac death, % 0.97% 1.10% 1.34% 1.29% 0.61
MI, % 1.43% 1.58% 2.05% 1.29% 0.35
CD-TLR, % 1.26% 1.27% 2.30% 1.65% 0.01
TVF, % 3.66% 3.73% 5.50% 5.33% 0.003
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neous coronary intervention (PCI) with drug-eluting stents (DES)
contribute to risk of subsequent death. Yet, the impact of the timing of
these events on subsequent mortality is less well understood.
METHODS ADAPT-DES was a large, prospective, multicenter registry
designed to identify the predictors of stent thrombosis. Patients
with successful PCI had assessment of platelet function and were
followed for 2 years. Events occurring after PCI – deﬁnite or probable
stent thrombosis (ST), myocardial infarction (MI) not related to
ST, and major bleeding (MB) were classiﬁed as early (30 days),
late (31-365 days) or very late (>365 days). Death within 12 months
of the events was analyzed by Kaplan-Meier techniques and a
Cox regression multivariable model was constructed to analyze the
relationship between each event – as a time-updated variable and
mortality.
RESULTS Among 8,582 patients, 294 had MI not related to ST (3.4%),
75 had ST (0.9%), 691 had MB (8.1%) and 7,522 had no event (87.6%)
during follow-up. Subsequent death within 2 years occurred in 12.4%
27.2%, 10.5%, and 2.7% of these patients respectively, P<0.0001. The
independent predictors of death were: increasing age, male sex, in-
sulin-requiring diabetes mellitus, MI before index PCI (>7 days),
chronic kidney disease, cigarette smoking, higher white blood cell
count, lower hemoglobin and lack of dual antiplatelet therapy (time-
adjusted). The time-adjusted relationship between these events
(corrected for the other events) and subsequent death, according to
the time of their occurrence, appears in the Table (reference
population is the group of patients without a particular event in the
speciﬁed time frame). High-platelet reactivity (HPR) and
presentation with acute coronary syndrome at index PCI were not
independent predictors of death, but HPR was highly predictive of
ST (P¼0.001), MI (P¼0.0006) and MB (P¼0.002).
CONCLUSIONS In an all-comers patient population treated with
DES, MI, ST and MB within 2 years are not uncommon (w1 in 8 pa-
tients). Early ST and early MI increased substantially the risk of
death, while MB had a less pronounced effect, emphasizing
the importance of improved devices, drugs and technique to prevent
their occurrence.Event typeHR [95%CI] for death after event occurrence according to event timingAny time £30 days 31 - 365 days >365 daysST 12.03 [8.05,
17.97]569.60 [197.36,
1643.89]8.33 [4.12, 16.83] 5.41 [2.39, 12.26]MI (no-ST) 2.00 [1.35, 2.94] 12.65 [1.47,
108.93]2.51 [1.37, 4.60] 3.22 [1.96, 5.28]MB 2.23 [1.71, 2.92] 2.80 [0.90, 8.68] 5.41 [3.75, 7.81] 2.82 [1.91, 4.17]CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Bleeding, Myocardial infarction, Stent thrombosis
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BACKGROUND Long coronary lesions have been associated with
worse clinical outcomes. Our aim was to assess one-year clinical
outcomes in real-world patients with different length of lesions after
implantation of bioresorbable polymer drug eluting stent (DES).
METHODS We analyzed data of unselected patients who received
Nobori Biolimus A9 eluting stent within the large, prospective,
single-arm, multicentre e-NOBORI registry. The primary endpoint
was target lesion failure (TLF) deﬁned as composite of cardiac
death, target vessel related myocardial infarction (MI) and clinically
driven target lesion revascularization at 1-year. An independent
clinical events committee adjudicated all endpoint related adverse
events.
RESULTS A total of 11919 patients were included in the analysis, of
which 44.1%, 38.2%, 13.1% and 4.6% had stent lesion  20mm,
20-40mm, 40-60mm and >60mm, respectively. The mean age did not
differ across four subgroups. There were more male patients with
increased lesion length across groups (Table). The proportion of
diabetic patients (33.2 %, 31.4%, 32.5%, 36.8%, P¼0.036),
hypertensive patients (71.0%, 70.5%, 73.3%, and 75.7, p¼0.021) and
current smokers (26.7%, 27.6%, 26.4% and 21.6%, P¼0.038) werealso different across subgroups. Other basic characteristics such as
previous MI and pervious stroke did not differ (p0.21). LAD was
the most frequent (45.2%) target vessel in stent lesion  20 mm
group, while RCA was the most frequent (41.1%) target vessel in
stent lesion > 60mm group. Complex lesion type (B2þC) were
45.4%, 59.6%, 62.6% and 65.7% across the groups. Total number of
lesions treated per patient were 1.71.6, 2.01.3, 2.61.4 and
3.51.9 respectively (P<0.01). Number of stents per lesion were
1.10.3, 1.20.4, 1.30.5 and 1.50.8 (p<0.01) respectively. There
were no differences in diameter stenosis at baseline (on average
84.8%, p¼0.60) while after procedure they were 2.8%, 2.9%, 1.9%
and 2.6% (P<0.01) respectively. At 1 year, there was no difference
(P>0.35) in the rate of any death, cardiac death, and MI (Table).
Composite endpoints TLF was slightly higher in long lesion
subgroups (2.9%, 3.4%, 4.7% and 4.2% respectively, p¼0.005). The
rate of stent thrombosis was low and comparable across 4
subgroups (0.38%, 0.55%, 0.77% and 0.18%, p¼0.16).CONCLUSIONS In a real-life practice registry, patients with long
lesions showed favorable and similar clinical outcomes when treated
with Nobori Biolimus A9 eluting stent. Although we cannot
completely exclude the possibility of underreporting of events,
especially of periprocedural MIs, the comparable and very low rate of
stent thrombosis across different lesion length groups up to 1 year is
encouraging.
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BACKGROUND We investigated whether non-invasive discrimination
of chronic total occlusion (CTO), a complete interruption of coronary
artery ﬂow, and subtotal occlusion (STO), a functional total occlusion,
is feasible using coronary computed tomography angiography (CTA).
CTO and STO may be different in pathophysiology and clinical treat-
ment strategy.
METHODS We included 486 consecutive patients (median age 63
years, male gender 82%) who showed a total of 553 completely
occluded coronary arteries in coronary CTA. The length of occlusion,
side branches, the shape of proximal stump, and collateral vessels
were measured as anatomical ﬁndings. Transluminal attenuation
gradient (TAG), which reﬂects intraluminal contrast kinetics and
functional extent of collateral ﬂow, was measured as a physiological
surrogate. All patients were followed by invasive coronary angiog-
raphy (CAG).
RESULTS Coronary arteries with CTO showed longer occlusion
length (cutoff 15 mm), higher TAG distal (cutoff  -0.9 HU/10mm),
more frequent side branches, blunted stump, cross-sectional
